Maplight - An experimental drug to moderate behavioural symptoms in people with autism

A clinical trial to investigate the efficacy, safety and tolerability of ML-004 for treatment of the core behavioural symptoms in Autistic people


The study evaluates the safety, efficacy and tolerability of investigational drug ML-004, compared to placebo, for treatment of the core symptoms in Autistic people.  The study will determine whether treatment with ML-004 results in improved social communication, as well as other aspects of autism.

Trial Status
Trial Phase
Phase 0
Trial contact details
Contact Person
Delphine Lévy-Bencheton
What you need to know

Who can take part?

Participants must:

  • be aged 15 to 45 years and diagnosed with Autism Spectrum Disorder
  • not be currently taking most psychotropic medications, including SSRI and SNRI antidepressants.
  • have a reasonable degree of social difficulties
  • have someone who lives with them or knows them very well who can attend appointments and complete questionnaires.
  • be able to reliably swallow oral pills
  • must avoid pregnancy during the study if the participant is of childbearing potential

What is involved for you?

The study treatment is a tablet taken once daily by mouth, which contains either the compound ML-004 or placebo. ML-004 has been available as a migraine treatment for several years.

The study investigations include:

  • Questionnaires for the participant and support person
  • Physical examination and vital signs
  • Electrocardiogram (ECG)
  • Video eye-tracking tests
  • Blood tests
  • Urine tests

All research clinical trials news

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.



Mater launches trial of Australian-first flu vaccine

Stephanie Guilas has worked in many departments throughout Mater Hospital Brisbane, however, after 28 years of service, she found her true passion working within Mater Research’s Mothers and Babies...



Stephanie Guilas is improving outcomes for mums and bubs through research

Working as a research assistant in an immunology research lab, Yvonne Gautam learnt what a clinical trial was after being asked to set up a lab for a Phase Two clinical trial.



Clinical Trials Coordinator Yvonne Gautam is working towards creating better treatments for patients with diabetes

Displaying results 1-3 (of 16)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|